Core Viewpoint - The article emphasizes the commitment of AbbVie to participate in the development of the biopharmaceutical ecosystem in Shandong, China, highlighting the importance of international collaboration and innovation in the industry [1][3]. Group 1: Company Strategy - AbbVie views Shandong as a critical strategic hub for its operations in China, having already engaged in over 30 clinical studies with local medical institutions [3]. - The company plans to increase its investment in China, aiming to accelerate global synchronized research and product launches [3]. Group 2: Future Projections - AbbVie anticipates launching more than 40 new products in China by 2030, reflecting its long-term commitment to the Chinese market [3].